全文获取类型
收费全文 | 1453224篇 |
免费 | 125514篇 |
国内免费 | 12769篇 |
专业分类
耳鼻咽喉 | 17864篇 |
儿科学 | 44820篇 |
妇产科学 | 39327篇 |
基础医学 | 195718篇 |
口腔科学 | 38842篇 |
临床医学 | 135350篇 |
内科学 | 295194篇 |
皮肤病学 | 33353篇 |
神经病学 | 116024篇 |
特种医学 | 59488篇 |
外国民族医学 | 314篇 |
外科学 | 222459篇 |
综合类 | 50575篇 |
现状与发展 | 22篇 |
一般理论 | 426篇 |
预防医学 | 114916篇 |
眼科学 | 31336篇 |
药学 | 106516篇 |
119篇 | |
中国医学 | 8676篇 |
肿瘤学 | 80168篇 |
出版年
2021年 | 13471篇 |
2019年 | 12585篇 |
2018年 | 17194篇 |
2017年 | 14215篇 |
2016年 | 15972篇 |
2015年 | 19372篇 |
2014年 | 26469篇 |
2013年 | 36462篇 |
2012年 | 46096篇 |
2011年 | 49473篇 |
2010年 | 31711篇 |
2009年 | 29896篇 |
2008年 | 43920篇 |
2007年 | 46273篇 |
2006年 | 47005篇 |
2005年 | 44951篇 |
2004年 | 41381篇 |
2003年 | 40046篇 |
2002年 | 37327篇 |
2001年 | 68779篇 |
2000年 | 70413篇 |
1999年 | 58940篇 |
1998年 | 17956篇 |
1997年 | 16130篇 |
1996年 | 16130篇 |
1995年 | 17050篇 |
1994年 | 15871篇 |
1993年 | 14547篇 |
1992年 | 47780篇 |
1991年 | 46400篇 |
1990年 | 44493篇 |
1989年 | 42265篇 |
1988年 | 39156篇 |
1987年 | 38424篇 |
1986年 | 36139篇 |
1985年 | 34846篇 |
1984年 | 26478篇 |
1983年 | 22202篇 |
1982年 | 13884篇 |
1981年 | 12486篇 |
1979年 | 23618篇 |
1978年 | 17121篇 |
1977年 | 14409篇 |
1976年 | 13192篇 |
1975年 | 13738篇 |
1974年 | 16141篇 |
1973年 | 15442篇 |
1972年 | 14242篇 |
1971年 | 13063篇 |
1970年 | 11896篇 |
排序方式: 共有10000条查询结果,搜索用时 721 毫秒
1.
2.
3.
目的分析盐酸利托君治疗晚期先兆流产保胎患者的临床疗效及不良反应发生率。方法选取2019年6—12月本院收治的行硫酸镁保胎治疗的35例晚期先兆流产患者作为对照组,另选取2020年1—7月本院收治的行盐酸利托君保胎治疗的35例晚期先兆流产患者作为研究组,比较两组治疗情况、保胎成功率、不良反应发生率、新生儿Apgar评分。结果研究组宫缩消失时间、止血时间、腹痛缓解时间、腰痛缓解时间、起效时间均短于对照组,且延长孕期时间长于对照组(P<0.05);研究组保胎成功33例(94.29%),对照组保胎成功26例(74.29%),差异有统计学意义(P<0.05);研究组不良反应发生率为22.86%,低于对照组的20.00%,但差异无统计学意义;研究组Apgar评分高于对照组,差异有统计学意义(P<0.05)。结论盐酸利托君治疗晚期先兆流产保胎患者,可尽快改善患者临床症状,有助于提高保胎成功率,改善母婴结局,且无明显不良症状,安全性较高,值得临床推广。 相似文献
4.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献
5.
6.
Journal of Behavioral Medicine - Evidence supports the use of graphic warnings to educate the public about the health harms of smoking and suggests warnings eliciting negative emotional responses... 相似文献
7.
8.
Qian Zhang Larry D. Mesner Gina M. Calabrese Naomi Dirckx Zhu Li Angela Verardo Qian Yang Robert J. Tower Marie-Claude Faugere Charles R. Farber Thomas L. Clemens 《The Journal of clinical investigation》2021,131(7)
Bone mineral density (BMD) is a highly heritable predictor of osteoporotic fracture. GWAS have identified hundreds of loci influencing BMD, but few have been functionally analyzed. In this study, we show that SNPs within a BMD locus on chromosome 14q32.32 alter splicing and expression of PAR-1a/microtubule affinity regulating kinase 3 (MARK3), a conserved serine/threonine kinase known to regulate bioenergetics, cell division, and polarity. Mice lacking Mark3 either globally or selectively in osteoblasts have increased bone mass at maturity. RNA profiling from Mark3-deficient osteoblasts suggested changes in the expression of components of the Notch signaling pathway. Mark3-deficient osteoblasts exhibited greater matrix mineralization compared with controls that was accompanied by reduced Jag1/Hes1 expression and diminished downstream JNK signaling. Overexpression of Jag1 in Mark3-deficient osteoblasts both in vitro and in vivo normalized mineralization capacity and bone mass, respectively. Together, these findings reveal a mechanism whereby genetically regulated alterations in Mark3 expression perturb cell signaling in osteoblasts to influence bone mass. 相似文献
9.
10.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.